Testing for All RAS Mutations in Colorectal Cancer

Such testing should be performed given that resistance to EGFr agents is associated with any RAS mutation.

Treatment for metastatic colorectal cancer (mCRC) has improved during the past decade with more active chemotherapy regimens and agents targeting the vascular endothelial growth factor and epidermal growth factor receptor (EGFr) pathways. However, the benefits of the EGFr-targeted agents panitumumab and cetuximab are limited to patients with wild-type KRAS status, and recent data have indicated that any RAS mutation results in resistance to EGFr agents.

To investigate this issue further, investigators have conducted the multicenter, randomized, phase II PEAK trial of modified FOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) plus either panitumumab (6 mg/kg) or bevacizumab (5 mg/kg) once every two weeks in patients with KRAS wild-type mCRC…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Testing for All RAS Mutations in Colorectal Cancer

Topics

Reviewing Author